{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T09:49:32Z","timestamp":1756460972191},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,7,9]],"date-time":"2011-07-09T00:00:00Z","timestamp":1310169600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1007\/s10620-011-1816-6","type":"journal-article","created":{"date-parts":[[2011,7,8]],"date-time":"2011-07-08T17:17:32Z","timestamp":1310145452000},"page":"221-231","source":"Crossref","is-referenced-by-count":7,"title":["Antiviral Drug Resistance Testing in Patients with Chronic Hepatitis B"],"prefix":"10.1007","volume":"57","author":[{"given":"Vincent Wai-Sun","family":"Wong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace Lai-Hung","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Hang","family":"Tse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lilly K. W.","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hoi-Yun","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen A.","family":"Locarnini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry Lik-Yuen","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,7,9]]},"reference":[{"key":"1816_CR1","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1055\/s-2006-939753","volume":"26","author":"HL Chan","year":"2006","unstructured":"Chan HL, Sung JJ. Hepatocellular carcinoma and hepatitis B virus. Semin Liver Dis. 2006;26:153\u2013161.","journal-title":"Semin Liver Dis"},{"key":"1816_CR2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","volume":"295","author":"CJ Chen","year":"2006","unstructured":"Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65\u201373.","journal-title":"JAMA"},{"key":"1816_CR3","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1200\/JCO.2009.26.2675","volume":"28","author":"VW Wong","year":"2010","unstructured":"Wong VW, Chan SL, Mo F, et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol. 2010;28:1660\u20131665.","journal-title":"J Clin Oncol"},{"key":"1816_CR4","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1111\/j.1365-2036.2008.03816.x","volume":"28","author":"JJ Sung","year":"2008","unstructured":"Sung JJ, Tsoi KK, Wong VW, Li KC, Chan HL. Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther. 2008;28:1067\u20131077.","journal-title":"Aliment Pharmacol Ther"},{"key":"1816_CR5","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.cgh.2009.05.025","volume":"7","author":"VW Wong","year":"2009","unstructured":"Wong VW, Wong GL, Chim AM, et al. Surrogate end points and long-term outcome in patients with chronic hepatitis B. Clin Gastroenterol Hepatol. 2009;7:1113\u20131120.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1816_CR6","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12072-008-9080-3","volume":"2","author":"YF Liaw","year":"2008","unstructured":"Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;2:263\u2013283.","journal-title":"Hepatol Int"},{"key":"1816_CR7","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol. 2009;50(2):227\u2013242.","DOI":"10.1016\/j.jhep.2008.10.001"},{"key":"1816_CR8","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.23190","volume":"50","author":"AS Lok","year":"2009","unstructured":"Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661\u2013662.","journal-title":"Hepatology"},{"key":"1816_CR9","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1053\/jhep.2001.25084","volume":"33","author":"NW Leung","year":"2001","unstructured":"Leung NW, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3\u00a0years of therapy. Hepatology. 2001;33:1527\u20131532.","journal-title":"Hepatology"},{"key":"1816_CR10","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1177\/135965350801300407","volume":"13","author":"VW Wong","year":"2008","unstructured":"Wong VW, Wong GL, Tsang SW, et al. Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B. Antivir Ther. 2008;13:571\u2013579.","journal-title":"Antivir Ther"},{"key":"1816_CR11","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1053\/j.gastro.2006.09.020","volume":"131","author":"SJ Hadziyannis","year":"2006","unstructured":"Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5\u00a0years. Gastroenterology. 2006;131:1743\u20131751.","journal-title":"Gastroenterology"},{"key":"1816_CR12","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1053\/j.gastro.2003.09.033","volume":"125","author":"AS Lok","year":"2003","unstructured":"Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology. 2003;125:1714\u20131722.","journal-title":"Gastroenterology"},{"key":"1816_CR13","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1053\/j.gastro.2008.10.026","volume":"136","author":"YF Liaw","year":"2009","unstructured":"Liaw YF, Gane E, Leung N, et al. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 2009;136:486\u2013495.","journal-title":"Gastroenterology"},{"key":"1816_CR14","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/hep.21189","volume":"43","author":"YS Lee","year":"2006","unstructured":"Lee YS, Suh DJ, Lim YS, et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48\u00a0weeks of adefovir dipivoxil monotherapy. Hepatology. 2006;43:1385\u20131391.","journal-title":"Hepatology"},{"key":"1816_CR15","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/jmv.10185","volume":"68","author":"HL Chan","year":"2002","unstructured":"Chan HL, Chui AK, Lau WY, et al. Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation. J Med Virol. 2002;68:182\u2013187.","journal-title":"J Med Virol"},{"key":"1816_CR16","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.1572-0241.2002.05478.x","volume":"97","author":"HL Chan","year":"2002","unstructured":"Chan HL, Tsang SW, Liew CT, et al. Viral genotype and hepatitis B virus DNA levels are correlated with histological liver damage in HBeAg-negative chronic hepatitis B virus infection. Am J Gastroenterol. 2002;97:406\u2013412.","journal-title":"Am J Gastroenterol"},{"key":"1816_CR17","first-page":"125","volume":"95","author":"A Ayres","year":"2004","unstructured":"Ayres A, Locarnini S, Bartholomeusz A. HBV genotyping and analysis for unique mutations. Methods Mol Med. 2004;95:125\u2013149.","journal-title":"Methods Mol Med"},{"key":"1816_CR18","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1053\/j.gastro.2007.08.079","volume":"133","author":"P Lampertico","year":"2007","unstructured":"Lampertico P, Vigano M, Manenti E, Iavarone M, Sablon E, Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology. 2007;133:1445\u20131451.","journal-title":"Gastroenterology"},{"key":"1816_CR19","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jhep.2008.01.027","volume":"48","author":"S Villet","year":"2008","unstructured":"Villet S, Pichoud C, Billioud G, et al. Impact of hepatitis B virus rtA181V\/T mutants on hepatitis B treatment failure. J Hepatol. 2008;48:747\u2013755.","journal-title":"J Hepatol"},{"key":"1816_CR20","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/hep.22295","volume":"48","author":"N Warner","year":"2008","unstructured":"Warner N, Locarnini S. The antiviral drug selected hepatitis B virus rtA181T\/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology. 2008;48:88\u201398.","journal-title":"Hepatology"},{"key":"1816_CR21","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa051285","volume":"354","author":"TT Chang","year":"2006","unstructured":"Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354:1001\u20131010.","journal-title":"N Engl J Med"},{"key":"1816_CR22","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/hep.22841","volume":"49","author":"DJ Tenney","year":"2009","unstructured":"Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5\u00a0years of therapy. Hepatology. 2009;49:1503\u20131514.","journal-title":"Hepatology"},{"key":"1816_CR23","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/s12072-009-9162-x","volume":"4","author":"Y Karino","year":"2010","unstructured":"Karino Y, Toyota J, Kumada H, et al. Efficacy and resistance of entecavir following 3\u00a0years of treatment of Japanese patients with lamivudine-refractory chronic hepatitis B. Hepatol Int. 2010;4:414\u2013422.","journal-title":"Hepatol Int"},{"key":"1816_CR24","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1007\/s12072-010-9185-3","volume":"4","author":"T Ide","year":"2010","unstructured":"Ide T, Sata M, Chayama K, et al. Evaluation of long-term entecavir treatment in stable chronic hepatitis B patients switched from lamivudine therapy. Hepatol Int. 2010;4:594\u2013600.","journal-title":"Hepatol Int"},{"key":"1816_CR25","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jhep.2008.08.020","volume":"50","author":"B Degertekin","year":"2009","unstructured":"Degertekin B, Hussain M, Tan J, Oberhelman K, Lok AS. Sensitivity and accuracy of an updated line probe assay (HBV DR v.3) in detecting mutations associated with hepatitis B antiviral resistance. J Hepatol. 2009;50:42\u201348.","journal-title":"J Hepatol"},{"key":"1816_CR26","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1177\/135965350601100810","volume":"11","author":"C Ding","year":"2006","unstructured":"Ding C, Wong VW, Chow KC, et al. Quantitative subtyping of hepatitis B virus reveals complex dynamics of YMDD motif mutants development during long-term lamivudine therapy. Antivir Ther. 2006;11:1041\u20131049.","journal-title":"Antivir Ther"},{"key":"1816_CR27","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3851\/IMP1496","volume":"15","author":"YY Lui","year":"2010","unstructured":"Lui YY, Tsoi KK, Wong VW, et al. Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy. Antivir Ther. 2010;15:145\u2013155.","journal-title":"Antivir Ther"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-011-1816-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-011-1816-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-011-1816-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T01:38:22Z","timestamp":1686188302000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-011-1816-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,9]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["1816"],"URL":"https:\/\/doi.org\/10.1007\/s10620-011-1816-6","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,9]]}}}